REG - Shield Therapeutics - Result of General Meeting & Total Voting Rights

Shield TherapeuticsAnnouncement

24/12/2024 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241224:nRSX3188Ra&default-theme=true

RNS Number : 3188R  Shield Therapeutics PLC  24 December 2024

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Result of General Meeting and Total Voting Rights

 

Shareholder approval for $10 million Subscription and Panel Waiver

 

London, UK, 24 December 2024: Shield Therapeutics plc (LSE: STX) is pleased to
announce that, at the General Meeting held earlier today, all Resolutions
(including the Waiver Resolution) as set out in the Notice of General Meeting
contained in the Circular published on 6 December 2024, were duly passed.
Accordingly, subject to Admission, the Company has raised gross proceeds of
$10 million pursuant to the Subscription and in addition the Panel Waiver has
been approved.  Further, as announced on 23 December 2024, the RetailBook
Offer has also raised £96,715.83 (before expenses) for the Company.

 

Admission and Total Voting Rights

 

Following the General Meeting held earlier today, the Company will issue a
total of 259,634,117 new Ordinary Shares ("New Ordinary Shares") made up of
256,410,256 Subscription Shares and 3,223,861 RetailBook Offer Shares.

 

Application has been made to the London Stock Exchange for admission of the
New Ordinary Shares to trading on AIM. It is expected that Admission will
become effective and dealings in the New Ordinary Shares will commence on AIM
at 8.00 a.m. on 30 December 2024. The New Ordinary Shares will rank pari passu
in all respects with the Existing Ordinary Shares.

 

Following Admission, the total number of Ordinary Shares in the capital of the
Company in issue will be 1,041,690,484 with equal voting rights. No shares are
held in treasury.

 

This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company's share capital
pursuant to (i) the Company's Articles, (ii) the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules and/or (iii) the AIM Rules for
Companies issued by the London Stock Exchange plc as amended from time to
time.

 

Results of the meeting

 

Details of the results of the voting, by way of a poll vote, at the General
Meeting are set out below. Resolutions 1 to 2 are ordinary resolutions and
Resolution 3 is a special resolution.

 

 Resolution  Votes For    Votes For              Votes Against  Votes Against          Vote Withheld

                          (as % of votes cast)                  (as % of votes cast)

 1*          102,899,680  98.07%                 2,024,299      1.93%                  323,522,105
 2           426,064,758  99.51%                 2,108,199      0.49%                  273,127
 3           426,044,147  99.52%                 2,044,320      0.48%                  357,617

 

*Resolution 1 was taken on a poll of Independent Shareholders (as defined in
the Circular) in accordance with the requirements of the Takeover Code.

 

Resultant holding of AOP and members of its Concert Party

 

The following table sets out the shareholdings of AOP and each member of its
concert party following Admission:

 Shareholder              Number of Ordinary Shares held following Admission  Percentage of the Enlarged Share Capital following Admission

 AOP                      568,007,521                                         54.53
 Dr. Christian Schweiger  11,651,713                                          1.12
 Dr. Günther Krumpl       4,000,000                                           0.38
 Michael Steiger          625,000                                             0.06
 Total                    584,284,234                                         56.09

 

Capitalised terms used but not otherwise defined in this announcement shall
have the meanings ascribed to such terms in the Company's announcement at
11.30 a.m. on 6 December 2024, unless the context requires otherwise.

 

For further information please contact:

 

 Shield Therapeutics plc                                                                        www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Anders Lundstrom, CEO                                                                          +44 (0) 191 511 8500

 Santosh Shanbhag, CFO

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel / Patrick Birkholm                                                                 +44 (0)20 7418 8900

 Joint Broker

 Cavendish Ltd

 Geoff Nash / Rory Sale / Nigel Birks / Harriet                                                 +44 (0)20 7220 0500
 Ward

 Financial PR & IR Advisor
 Walbrook PR
 Alice Woodings / Lianne Applegarth                                                             +44 (0)20 7933 8780 or shield@walbrookpr.com (mailto:shield@walbrookpr.com)

 

About Iron Deficiency and ACCRUFeR®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health
problems for adults of all ages, across multiple therapeutic areas. Together,
ID and ID with anemia (IDA) affect about 20 million people in the US and
represent a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet
medical need for both physicians and patients.

 

ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral
therapy for adults with ID/IDA. The drug has a novel mechanism of absorption
compared to other oral iron therapies and has been shown to be an efficacious
and well-tolerated therapy in a range of clinical trials. More information
about ACCRUFeR®/FeRACCRU®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com) .

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers
ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated
pharmaceutical product, to address a significant unmet need for patients
suffering from iron deficiency, with or without anemia. The Company has
launched ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration
agreement with Viatris. Outside of the U.S., the Company has licensed the
rights to four specialty pharmaceutical companies. FeRACCRU® is
commercialized in the UK and European Union by Norgine B.V., which also has
marketing rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the
development and commercialization of ACCRUFeR®/ FeRACCRU® in China, Hong
Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea,
and with KYE Pharmaceuticals Inc. for Canada.

 

ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMBBBDDGDDDGSS